Progressive Supranuclear Palsy (Psp) Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
This page provides a comprehensive mechanistic pathway model for Progressive Supranuclear Palsy (PSP), a 4R-tauopathy characterized by tau aggregation in the basal ganglia and brainstem. The pathway model integrates genetic risk factors, molecular mechanisms, neuroanatomical progression, and therapeutic targets.
flowchart TD
A[Genetic Risk Factors] --> B[Tau Pathology](/mechanisms/tau-pathology)
C[MAPT H1 Haplotype] --> B
D[MAPT Mutations] --> B
B --> E[4R Tau Overproduction]
B --> F[Tau Mislocalization]
E --> G[Hyperphosphorylation]
F --> G
G --> H[Tau Aggregation]
H --> I[Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
H --> J[Tufted Astrocytes]
I --> K[Globose NFTs]
J --> L[Astrocytic Plaques]
K --> M[Brainstem Degeneration]
L --> M
M --> N[Substantia Nigra](/brain-regions/substantia-nigra)
M --> O[Red Nucleus](/cell-types/red-nucleus-expanded)
M --> P[Globus Pallidus](/brain-regions/globus-pallidus)
N --> Q[Dopaminergic Neuron Loss]
O --> R[Motor Dysfunction]
P --> R
Q --> S[Parkinsonism]
R --> T[Postural Instability]
S --> U[Vertical Gaze Palsy]
T --> U
U --> V[Frontal Cognitive Dysfunction]
V --> W[Executive Impairment]
V --> X[Behavioral Changes]
W --> Y[Progressive Disability]
X --> Y
T --> Y
| Protein/Gene | Function in PSP | Therapeutic Target |
|---|---|---|
| MAPT | Microtubule-associated protein tau; H1 haplotype increases risk; mutations cause 4R tau production | Tau aggregation inhibitors |
| 4R Tau | Four-repeat tau isoform; aggregates in PSP; toxic to neurons | Immunotherapy, aggregation inhibitors |
| GSK-3β | Kinase that phosphorylates tau at multiple sites | Kinase inhibitors |
| CDK5 | Kinase that hyperphosphorylates tau | Neuroprotective agents |
| PP2A | Phosphatase that dephosphorylates tau; activity reduced in PSP | Phosphatase activators |
| TREM2 | Microglial receptor; modulates neuroinflammation | TREM2 modulators |
The MAPT (microtubule-associated protein tau) gene on chromosome 17q21 is central to PSP pathogenesis:
Genome-wide association studies have identified additional risk loci:
| Subtype | Clinical Features | Pathology |
|---|---|---|
| Richardson's Syndrome | Classic PSP: vertical gaze palsy, postural instability, parkinsonism | Typical 4R tau pathology |
| PSP-Parkinsonism (PSP-P) | Parkinsonism predominant, less gaze palsy | Less severe tau pathology |
| PSP-PAGF | Pure akinesia with gait freezing | Predominant brainstem involvement |
| PSP-C | Cerebellar ataxia predominant | Cerebellar tau pathology |
| PSP-F | Frontal syndrome predominant | Frontal cortical involvement |
| Corticobasal Syndrome | Cortical sensory loss, alien limb | CBD-PSP overlap |
| Approach | Mechanism | Development Stage | Challenges |
|---|---|---|---|
| Tau Aggregation Inhibitors | Prevent tau polymerization | Preclinical/Phase 1 | Blood-brain barrier penetration |
| Tau Immunotherapy | Anti-tau antibodies to clear tau | Phase 1/2 | Antibody delivery to brain |
| GSK-3β Inhibitors | Block tau phosphorylation | Preclinical | Kinase selectivity |
| Microglial Modulation | Reduce neuroinflammation | Preclinical | Target specificity |
| Treatment | Target | Efficacy |
|---|---|---|
| Levodopa | Dopamine replacement | Mild, transient benefit |
| Amantadine | NMDA antagonist | Modest improvement |
| Clonazepam | GABA-A agonist | For gait freezing |
| Botulinum toxin | Muscle relaxation | For dystonia |
| Biomarker | Source | What it Measures |
|---|---|---|
| Total Tau | CSF | Neuronal damage |
| Phospho-tau (Thr181) | CSF | Tau pathology burden |
| Neurofilament Light Chain (NfL) | CSF, Blood | Disease progression |
| Tau PET | Brain imaging | Tau deposition |
The study of Progressive Supranuclear Palsy (Psp) Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Hoglinger GU. Advances in progressive supranuclear palsy and other neurodegenerative disorders. Lancet Neurol. 2017;16(7):534-548. PMID:28653647.
Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Acta Neuropathol. 2010;120(1):43-58. PMID:23359374.
Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of sporadic progressive supranuclear palsy. Nat Genet. 2011;43(10):1005-1011. PMID:21892162.
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9. PMID:8710059.
Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8(3):270-279. PMID:19233037.
Ghioni P, Padelli M, Bruzzone MG, et al. Tau in cerebrospinal fluid: a potential biomarker of disease progression in progressive supranuclear palsy? J Neurol Sci. 2020;415:116931. PMID:32229317.
Stamelou M, Hoeglinger GU. Atypical parkinsonism. Continuum (Minneap Minn). 2019;25(1):155-177. PMID:30676885.
Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective study of 100 cases. Mov Disord. 2014;29(3):349-356. PMID:24375326.
Colosimo C, Bak TH, Bologna M, Berardelli A. Fifty years of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2014;85(8):938-944. PMID:24385231.
Vandebergh M, Lubbe S, Peeters K, et al. Environmental risk factors for progressive supranuclear palsy. Mov Disord. 2021;36(11):2558-2567. PMID:34184731.
Jellinger KA. Neuropathology of progressive supranuclear palsy. J Neural Transm (Vienna). 2014;121(6):645-655. PMID:24249355.
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of progressive supranuclear palsy. Neurology. 2013;80(5):496-503. PMID:23359374.
Wenning GK, Litvan I. Update on progressive supranuclear palsy. J Neural Transm (Vienna). 2021;128(4):481-487. PMID:33782785.
Koga S, Kasanuki K, Briggs DE, et al. Diffusion-weighted MRI and PET in progressive supranuclear palsy. Parkinsonism Relat Disord. 2015;21(9):1064-1070. PMID:26209153.
McFarland NR, Hess CW. Recognizing atypical parkinsonisms: new frontiers in diagnosis and treatment. Continuum (Minneap Minn). 2017;23(5):1435-1455. PMID:28968368.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 38%